Nanomedicine: a pharma perspective

Nanotechnology as applied to medicine is not a new field. The first nanomedicines approved for use were developed from research dating back to the 1970s. These liposomal formulations of existing drugs showed improved therapeutic activity and reduced toxicity in the nonclinical model systems. However, these benefits proved more subtle and harder to demonstrate in patients. This fact, combined with the technical challenges in commercial-scale production of nanoparticles, led to only limited investment in nanomedicines by the major pharmaceutical companies. Even so, research on nanomedicines has proceeded apace in academic laboratories and smaller biopharmaceutical companies. New materials and drug combinations have been studied, and targeting moieties added with the aim of improving the therapeutic index. Today many of these new designs are in, or are approaching, clinical testing. It will take only one or two to be successful to change the way pharmaceutical companies view this field of innovative research. (C) 2014 Wiley Periodicals, Inc.WIREs Nanomed Nanobiotechnol 2015, 7:125-130. doi: 10.1002/wnan.1288 Conflict of interest: The authors have declared no conflicts of interest for this article. For further resources related to this article, please visit the .